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A study was undertaken to correlate telomere dysfunction and genomic instability with the histopathological grades and the
estrogen and progesterone receptor status in breast cancer. Sixty-one archived breast tissues (38 cancer tissues and 23 paired
normal tissues) were used in the study. The breast tumor tissues showed significantly shorter telomeres (7.7 kb) compared
with the paired adjacent tissues (9.0 kb) by Southern blot analysis. Moreover, telomere shortening was more significant in
Grade III tumors than in the Grade II tumors (P 5 0.05). Quantitative fluorescence in situ hybridization on paraffin tissue sec-
tions revealed a similar trend in telomere shortening. Telomere attrition was associated with telomere dysfunction as revealed
by the presence of significantly higher anaphase bridges in tumor cells which was tumor grade dependent. Furthermore, estro-
gen receptive negative tumors displayed higher anaphase and internuclear bridges. Selected samples from each grade showed
greater genomic imbalances in the higher grades than the lower grade tumors as detected by array-comparative genomic
hybridization. Telomerase activity was found to be higher in the higher grades (Grade II and III) compared with the lower grade
(Grade I). The average mRNA expression of TRF1 and POT1 was lower in the tumor tissues than in the normal tissues. Tankyr-
ase 1 mRNA expression showed a grade-dependent increase in tumor tissues and its expression was also high in estrogen and
progesterone negative tumors. The data support the notion that telomere dysfunction might be of value as a marker of aggres-
siveness of the tumors in breast cancer patients. VC 2008 Wiley-Liss, Inc.
INTRODUCTION
Breast cancer is the most common cause of can-
cer deaths among women worldwide (Chia et al.,
2002). Suitable biomarkers are necessary for assess-
ment of the tumors and proper clinical treatment
decisions. Tumor/nodes/metastases stages have
long been used as the most powerful indicators of
breast cancer prognosis and recurrence (Hayes
et al., 2001). In addition, a number of other markers
like tumor type and grade, hormonal receptor sta-
tus, markers of proliferation, cell death, micrometa-
stasis, and neovascularization provide additional in-
formation about the prognosis, response to treat-
ments, and recurrence (Hayes et al., 2001).
Increasing number of markers is being developed
to understand the disease prognosis and determine
the treatment options.
Genomic instability is an important factor in can-
cer initiation and progression (Hanahan and Wein-
berg, 2000; Meeker and Argani, 2004). Telomeres
and the associated telomeric proteins play signifi-
cant roles in maintaining the integrity of the ge-
nome. Loss of telomere function is one of the
mechanisms underlying genomic instability. Telo-
mere loss or dysfunction results in complex types
of genomic abnormalities, including loss of hetero-
zygosity, gene amplifications, deletions, and aneu-
ploidy (Lo et al., 2002; Murnane and Sabatier,
2004; Sabatier et al., 2005). Furthermore, the con-
sequential genomic instability has also been shown
to be associated with aggressiveness and poor prog-
nosis of tumors (Kronenwett et al., 2006). In carci-
nomas, histomorphologically increasing gradation
of dysplasia is associated with the aggressiveness of
the tumors. Hence, it is important and interesting
to understand the association of telomere dysfunc-
tion with the aggressiveness of the tumors.
The regulation of telomere length is a dynamic
process involving telomerase and a highly complex
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system involving a number of telomere-associated
proteins. Telomere repeat binding factor 1
(TRF1), protection of telomeres 1 (POT1), and
Tankyrase 1 (TRF1-interacting ankyrin-related
ADP ribose polymerase) are telomere-associated
proteins that are part of telomere structure and
have essential roles in telomere length regulation
(Liu et al., 2004a). TRF1 binds to TTAGGG dou-
ble stranded repeats of telomeres and has been
identified as a negative regulator (Bilaud et al.,
1996, 1997; Broccoli et al., 1997). Tankyrase 1
interacts with TRF1 and its over expression was
shown to release TRF1 from the telomeres and
induce telomere elongation. Tankyrase 1 has thus
been shown as a positive regulator of telomere
length (Smith et al., 1998). POT1 is recruited to
the 30 single-stranded portion of the telomeric
DNA and it was found to employ telomerase for
telomere elongation (Liu et al., 2004a,b; Smogor-
zewska and de Lange, 2004).
The aim of this study was to investigate the
association of telomere dysfunction and genomic
instability with the tumor prognostic factors like
histopathological grades and hormonal receptor
status. In addition, the mRNA expression of
selected telomere related genes such as TRF1,
Tankyrase 1, and POT1 were also studied.
MATERIALS ANDMETHODS
Patient Samples
Archived human invasive ductal breast carci-
noma with the paired adjacent tissues or DNA and
RNA samples (n 5 61; Tumor 5 38; Paired normal
5 23) were obtained from the Department of
Pathology, National University Hospital, Singa-
pore. This study was approved by National Univer-
sity of Singapore—Institutional Review Board
(NUS-IRB; NUS-062). The samples were histopa-
thologically graded based on the modified Scarff-
Bloom-Richardson grading system. Estrogen re-
ceptor (ER) and progesterone receptor (PR) status
of the tumor samples were also determined.
Telomere Restriction Fragment Length Analysis
Genomic DNA was isolated from the frozen tis-
sues using QIAamp Tissue Kit (Qiagen, Valencia,
CA). Telomere length was assessed by measuring
the telomere restriction fragments using the Telo
TTAGGG telomere length assay kit (Roche Diag-
nostics, Indianpolis, USA) by following manufac-
turer’s instructions. After digestion of the genomic
DNA with HinfI and RSAI, they were separated on
a 0.8% agarose gel. The DNA was then transferred
onto the nylon membrane (Roche Diagnostics,
Indianpolis, USA) by Southern blotting and the
blotted DNA fragments were hybridized to digoxi-
genin-labeled probe specific for telomeric repeats
and incubated with a digoxigenin-specific antibody
covalently coupled to alkaline phosphate. Finally,
the immobilized telomere probe was visualized by
metabolizing CDP-Star, a highly sensitive chemi-
luminescence substrate. The average TRF length
was determined by comparing the signals to a mo-
lecular weight standard using the Kodak Molecular
Imaging Software (Kodak, Rochester, USA).
Peptide Nucleic Acid–Fluorescence In Situ
Hybridization for Telomeres on Tissue Sections
Paraffin embedded tissue sections of 4-lm thick-
ness were deparaffinized in 100% Xylene. After
dehydrating with 100% ethanol, the slides were
incubated in 1 M sodium thiocyanate at 808C for 8
min. Slides were incubated in 1% pepsin in 0.01 M
HCl for 2 min at 378C and dipped through the
ethanol series and air dried. The tissue sections
were then hybridized with Cy3 conjugated PNA
telomere probe (Applied Biosystems, Boston, MA)
for 2 hr at room temperature after co-denaturation
at 808C for 3 min (Hande et al., 1999). Stringent
washes were performed and the slides were coun-
terstained with DAPI (0.1 lg/ml). Images were
captured with Zeiss Axioplan 2 imaging micro-
scope (Carl Zeiss, Gottingen, Germany) and the
telomere signals were quantitated using the ISIS
software (Metasystems, Altusseheim, Germany).
Telomerase Activity
The TRAPeze1 XL Telomerase Detection Kit
(Chemicon International, Temecula, CA) was used
according to the manufacturer’s instructions to
measure the telomerase enzyme activity of breast
cancer tissues and the paired adjacent tissues. The
breast tissue extract was prepared after homogeniz-
ing the cells and resuspending in 100 ll of CHAPS
XL Lysis Buffer (included in the telomerase detec-
tion kit) and incubating on ice for 30 min. The
extract was pelleted (12,000g at 48C), and the su-
pernatant was frozen at 2808C until assayed for
telomerase. The TRAPeze1 XL Telomerase
Detection Kit uses a modified TRAP (telomerase
repeat amplification protocol) assay to detect telo-
merase activity through the amplification of telo-
meric repeats using fluorescence energy transfer
primers (AmplifluorTM) that produce measurable
fluorescence only when incorporated into TRAP
products. The fluorescence of each reaction was
measured with a Magellan fluorescent plate reader.
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Telomerase activity of each sample was deter-
mined by calculating the ratio of the increase in
fluorescein absorbance (produced by the amplifica-
tion of telomeric repeats) divided by the increase
in sulforhodamine absorbance.
Anaphase Bridges and Internuclear Bridges
Anaphase bridges are chromosomal bridges that
are not resolved during anaphase and are associ-
ated with telomere dysfunction and chromosome
end fusions (Meeker and Argani, 2004; Jin et al.,
2007; Stewenius et al., 2007). The frequency of
anaphase bridges is commonly used as an indicator
of telomere-mediated chromosomal instability.
H&E stained paraffin sections were used to score
the anaphase and internuclear bridges. Fifty mi-
totic cells were scored for anaphase bridges and
500 nuclei were scored for internuclear bridges.
Array Comparative Genomic Hybridization
(Array-CGH) on Tissue Samples
Genomic DNA was extracted from the tissues
by phenol-chloroform method. Normal female
DNA (Promega, Madison, WI) was used as the
control DNA. DNA was run on a 1.2% agarose gel
to check for any degradation or RNA contamina-
tion and was quantitated by NanoDrop ND-1000
UV–vis spectrophotometer. Array-CGH (aCGH)
was performed according to the protocol suggested
by Agilent Technologies, Santa Clara, USA.
Genomic DNA was amplified using the Qiagen
REPLI-g mini kit (Qiagen, Valencia, CA). The
amplified genomic DNA was digested by AluI
(Promega, Madison, WI) and RsaI (Promega, Madi-
son, WI) on a 378C circulating water bath for 2 hr
and transferred onto ice. The amplified digested
genomic DNAwas cleaned up using QIAprep Spin
Miniprep Kit (Qiagen, Valencia, CA). DNA was
further quantitated using the NanoDrop ND-1000
UV–vis Spectrophotometer. It was then fluores-
cently labeled using random primers (supplied
with Agilent Genomic DNA labeling kit PLUS)
with Cyanine 3-dUTP (test) and Cyanine 5-dUTP
(control). The labeled genomic DNA was cleaned
using the Microcon YM-30 filters. Cy3-labeled and
Cy5-labeled genomic DNA were mixed with
human Cot-1 DNA (1 mg/ll) (Invitrogen, Carls-
bad, USA), Agilent 10x blocking agent and Agilent
2x hybridization buffer. The hybridization sample
mixture was applied to the gasket slide and then
the active side of the microarray slide was placed
on top of the gasket slide to form a ‘‘sandwich slide
pair.’’ The SureHyb chamber cover was placed
onto the sandwiched slides and the slide clamp
was assembled onto both pieces. The assembled
slide was then placed in the rotator rack in a
hybridization oven at 658C to rotate at 20 rpm and
left to hybridize at 658C for 40 hr. The slides were
disassembled in Oligo aCGH Wash Buffer 1 and
washed in Oligo aCGH Wash Buffer 1 at room
temperature for 5 min and in Oligo aCGH Wash
Buffer 2 at 378C for 1 min. The slides were
scanned immediately to minimize the impact of
environmental oxidants on signal intensities using
Agilent scanner that was set to scan area (61 3 21.6
mm2). Scan resolution was set to 10 using dye
channel red and green. Green and red photomulti-
plier tubes were set to 100%. Data analysis was
done using the CGH analytics software.
Quantitative Real-Time PCR
RNA was extracted from the frozen tissues by
TRIZOL method and quantitated by the nanodrop
spectrophotometer. The analyses of the TRF1,
Tankyrase 1, and POT1 mRNA expression were per-
formed using the Light Cycler RNA Master SYBR
Green Kit (Roche Diagnostics, Indianapolis) by
real-time quantitative RT-PCR. The primer
sequences for the genes are as follows: TRF1 for-
ward primer, 50-gca aca ggg cag agg cta tta tt-30;
TRF1 reverse primer, 50-agg gct gat tcc aag ggt gta
-30, Tankyrase 1 forward primer, 50-atg ccc cca gag
gcc tta-30; Tankyrase 1 reverse primer, 50-ggt gga tgc
tgg tga gat ca-30 and POT1 forward primer, 50-tca
gtc tgt taa ctt cat tgc cc -30; POT1 reverse primer,
50-tgc acc atc ctg aaa aat tat atc-30 (First base). The
house keeping gene 18S rRNAwas used to normal-
ize the sample-to-sample variation in the amount
of the input RNA, and also to evaluate the quality
of the isolated RNA and RT efficiency. Amplifica-
tion of the 18S rRNA was performed using the fol-
lowing primers: forward primer: 50 gta acc cgt tga
acc cca tt-30and reverse primer: 50 cca tcc aat cgg
tag tag cg 30. PCRs were performed in a Light-
Cycler1 instrument (Roche Diagnostics) as fol-
lows: reverse transcription at 618C for 20 min, ini-
tial denaturation at 958C for 2 min; amplification
for 45 cycles of denaturation (958C, 5 sec, ramp
rate 28C/sec), annealing (optimal temperature, 5
sec, ramp rate 28C/sec) and extension (728C, prod-
uct length [bp]/25 sec, ramp rate 28C/sec). The
standard curve was constructed with 10-fold serial
dilutions of the RNA which corresponded to the
total RNA ranging from 0 to 500 ng. The PCR
reaction for amplification was performed using 500
ng of the total RNA for the target genes and 5 ng
for the house keeping gene. All of the measure-
ments included the determination of the standards
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and no-template as a negative control, in which
water was substituted for the RNA. Data for TRF1
mRNA, POT1 mRNA and Tankyrase 1 mRNA were
normalized to the data for 18 s RNA. The products
were run on a 1% agarose gel to confirm the size of
the final product for all of the genes.
Statistical Analyses
Statistical analyses of the data were done by
unequal variance t test (Welch test) using Micro-
soft Excel 2007 (Microsoft Corporation, Redmond,
USA) (Ruxton, 2006).
RESULTS
Significantly Greater Telomere Shortening in the
Higher Grades of Breast Cancer Samples
Paired adjacent tissues were found to have lon-
ger TRFs (Mean 6 SD and range: 9.0 6 2 kb and
6.8–13.2 kb) than in the breast tumor tissues
(Mean 6 SD and range: 7.7 6 0.63 kb and 6.7–10
kb). The difference in length was statistically sig-
nificant (P < 0.05) (Fig. 1A). The average percent-
age decrease was more significant in Grade III
tumors (P < 0.05) than in the Grade II tumors
(P 5 0.05) (Fig. 1A). To gain further insights into
the telomere length changes, we have used in situ
analysis of telomere length by quantitative-fluores-
cence in situ hybridization on paraffin tissue.
Quantitative-fluorescence in situ hybridization
analysis yielded similar reductions in telomere
lengths in tumor tissues compared with the adja-
cent tissues (Fig. 1B).
Higher Telomerase Activity in Breast Cancer
Samples than in the Adjacent Tissues
Telomere dysfunction results from critically
short telomeres or the loss of stability of the telo-
mere secondary structure. The telomere length is a
balance between its loss due to the cell prolifera-
tion and the maintenance by telomerase. Hence,
we decided to look at the status of telomerase in
relation to the aggressiveness of the tumors. Telo-
merase activity was detected in all the cancerous
tissues, and it was about 1.5 times more in the
higher grades (Grade II and III) than the lower
grade (Grade I) tumors (Fig. 1C). We have also
detected low levels of telomerase activity in about
66% of the paired adjacent tissues; however, this
was about 20 times lower than that detected in the
cancerous tissues. There was no correlation
between the telomerase activity and other clinico-
pathological parameters such as hormonal receptor
status, lymph node status, or the HER2/neu status
(Data not shown).
Telomere Attrition Associated with Elevated
Chromosome Instability in the Higher Grades
To determine whether the telomere shortening
observed in the higher grade tumors was associated
with telomere dysfunction, the percentage of ana-
phase bridge formation was analyzed. Telomere
shortening may compromise the integrity of chro-
mosome ends and lead to the formation of dicen-
trics and rings. These abnormal structures may
form bridges at anaphase that either break or initi-
ate a series of breakage-fusion-bridge events.
Thus, anaphase bridges are chromatin bridges in
between separating chromosome masses during
anaphase, which may result in gene amplification
or loss when breaking (Lengauer, 2001). Anaphase
bridge formation is a correlate of telomere dysfunc-
tion (Meeker and Argani, 2004; McPherson et al.,
2006; Jin et al., 2007; Stewenius et al., 2007). There
was a fivefold increase in the frequency of ana-
phase bridges in Grade III from Grade I (P < 0.05)
in breast tumor samples (Fig. 2A). Internuclear
bridges that are also indicative of chromosomal
instability showed a threefold increase in fre-
quency from Grade I to grade III (P < 0.01) and
twofold from Grade I to Grade II (P < 0.05) (Fig.
2B) breast cancers. Thus, telomere shortening was
correlated with telomere dysfunction which was
concurrent with the histological grading. Telomere
dysfunction in the form of anaphase bridges also
correlated with the estrogen receptor status where
the frequency was higher in ER-negative tumors
(Table 1). ER status has also been associated with
the prognosis of breast cancers with ER- negative
tumors having worse prognosis than ER-positive
tumors. However, the increased percentage of ana-
phase bridges in PR-negative compared to PR-pos-
itive tumors was not statistically significant.
Increased Genomic Imbalances in the Form of
Amplifications or Deletions in Higher Grades of
Breast Cancer by aCGH
Telomere-mediated chromosome rearrange-
ments cause genomic imbalances, which were
measured by aCGH. We used selected samples
(six samples; two from each grade) to measure
genomic imbalances by aCGH. Our results showed
greater genomic imbalances in the form of dele-
tions and amplifications in the higher grade tumors
compared with the lower grade tumors (Figs. 3A
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Figure 1. Average percent decrease in telomere length in different
grades of tumors. A: (a) Telomere length measured by Southern blot-
ting of the terminal restriction fragments. Grade I tumors showed
4.76% decrease, Grade II tumors showed 9.76% decrease, and Grade III
tumors showed 18.86% decrease in telomere length on an average
when compared with the paired adjacent tissues. *P < 0.05. (b) Repre-
sentative samples of telomere length analysis by Southern blotting for
Grade I and Grade III tumors are shown here. N, normal; T, tumor;
L, control low; H, control high; M, marker. Bars indicate SE. B: (a) Telo-
mere length measured on paraffin tissue sections by PNA FISH. Grade I
tumors showed 2.8% decrease, Grade II tumors showed 9.9% decrease,
and Grade III tumors showed 16.86% decrease in telomere length on
an average when compared with the paired adjacent tissues. Bars indi-
cate SE. (b) Representative pictures of tissue FISH in the paraffin sec-
tions of Grade I, II, and III tumors showing telomere signals using the
telomere specific Cy-3 labeled PNA probe. *P < 0.05. C: Average telo-
merase activity (D Fluorescein/D Sulforhodamine) in the breast cancer
tissues and the paired adjacent tissues. The solid bars are the cancer
tissue samples and the white bars are the paired adjacent tissue sam-
ples. Bars indicate SE. *P < 0.05.
and 3B). Studies are in progress to determine the
nature of these genes in breast tumors.
Differential Expression of mRNA for TRF1, POT1,
and TANKYRASE 1 in Relation to the Histological
Grades of the Tumors
As mentioned earlier, in addition to telomerase,
a number of telomere associated proteins have
been shown to play a role in maintaining telomere
integrity. We looked at the mRNA expression of
some of the positive and negative regulators of
telomere length. TRF1 showed a heterogeneous
pattern of expression in the samples. However, on
average, the expression of TRF1 mRNAwas higher
in adjacent tissues compared with the tumor tis-
sues. On the other hand, when compared between













Grade I 4.77 3.22 0.00011 1.8 E2088 0.46
Grade II 12.99b 16.67c 0.00018 3.1 E208c 0.02
Grade III 19.19c 20.03c 0.00017 1.9 E207 0.24
Oestrogen receptor (ER) status
Negative 14.78 20.95d 0.00014d 2.4 E207d 0.34
Positive 12.14 12.67 0.00032 3.1 E208 0.12
Progesterone receptor (PR) status
Negative 16.14 19.86 0.00022 2.2 E207e 0.26
Positive 9.62 13.05 0.00021 3.1 E208 0.15
Lymph node metastasis
Absent 13.06 16.30 0.00021 9.8 E208 0.33
Present 14.46 18.10 0.00024 2.1 E207 0.29
Tumour size
<2 cm 9.27 23.65 0.00048 3.1 E208 0.30
2 cm 14.15 16.20 0.00019 1.5 E207 0.31
aNormalized values for the expression of the target genes to the normal house keeping gene (18s rRNA) expression.
bP 5 0.05 (compared with paired adjacent tissue samples).
cP < 0.05 (compared with paired adjacent tissue samples).
dP < 0.05 (compared with ER positive samples).
eP < 0.05 (compared with PR positive samples).
Figure 2. Anaphase bridges as an indicator of telomere dysfunction.
A: (a) Average percentage of anaphase bridge formation in all of the
three grades of tumors. Grade I tumors had 3.3%, Grade II 16.6%, and
Grade III 20.7% of anaphase bridges. *P < 0.05. (b) Anaphase bridges in
Haematoxylin and eosin (H&E) stained tumor paraffin sections. B: (a)
Average percentage of internuclear bridges in all of the three grades of
tumors. Grade I tumors had 0.7%, Grade II 4.75%, and Grade III 6.32%
of internuclear bridges. *P< 0.01. (b) Internuclear bridge in Haematoxy-
lin and eosin (H&E) stained tumor paraffin sections. Results are shown
in percentage 6 SE.
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grades the TRF1 expression did not show a signifi-
cant trend, but was higher in the lower grades than
the higher grades (Fig. 4A and Table 1). Average
expression of POT1 mRNA appears to be down-
regulated in cancer tissues. The expression was
observed to be higher, but not statistically signifi-
cant P > 0.05), in the early grade (Grade I) com-
pared with the latter grades (Grade II and III) (Fig.
4B). Tankyrase 1 mRNA expression was signifi-
cantly higher in cancerous tissues compared with
the adjacent tissues. There was also an increase
in the mRNA expression from lower grades to
higher grades (Fig. 4C and Table 1). Its expression
was also high in ER- and PR-negative tumors
(Table 1).
DISCUSSION
Breast cancer patients are often classified into
those with favorable (well-differentiated tumors)
or less favorable (poorly-differentiated tumors) out-
come using prognostic markers. Histopathological
grading is widely accepted and a good prognostic
indicator of breast cancer and prospectively used in
the clinical treatment decisions (Dalton et al.,
2000; Ellsworth et al., 2008). The cells in Grade I
tumors resemble normal cells and appear to grow
and multiply slowly, whereas higher grade tumors
grow rapidly and are poorly differentiated. Geneti-
cally unstable tumors have been shown to be larger
in size and to be at higher grade compared with the
stable tumors (Christov et al., 1989; Kronenwett
et al., 2006). Genomic instability contributes to a
major problem in management of breast cancer
phenotypes because of their more aggressive pheno-
type and chemo-resistance (Loeb, 2001; Chin
et al., 2004).
Telomere dysfunction may be one of the molec-
ular causes of genomic instability. We have
reported the telomere dysfunction phenotype in
BRCA1-deficient cells suggesting the fact that loss
Figure 3. Array-CGH analysis in breast tumor samples. A: Com-
plete genome view by array-CGH showing greater genomic instability
in the higher grade than the lower grade of tumors. Log2 11.0 horizon-
tal scale bars (above which is considered amplification) and Log2 21.0
horizontal scale bars (below which is considered deletions) are included
for reference. B: Chromosome 5 used as a representative chromosome
shows greater genomic imbalances in the higher grades than the lower
grades. Green dots represent deletions and red dots represent amplifi-
cations.
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of telomere integrity might contribute to chromo-
some end dysfunction and permit the formation of
potentially oncogenic translocations (McPherson
et al., 2006). Breast cancer patients exhibited sig-
nificant chromosome instability and telomere loss
following radiotherapy, which suggests that there is
marked increase in telomere dysfunction in breast
cancer patients (Banerjee et al., 2008). Recent
studies in bladder cancer (Jin et al., 2007) and
Wilms’ tumor (Stewenius et al., 2007) demon-
strated telomere shortening and telomere dysfunc-
tion in higher grade tumors. Evidence from our
study support the hypothesis that telomere dys-
function impairs chromosomal stability and is asso-
ciated with the aggressiveness of the tumors. The
breast cancer cells have infinite replicative poten-
tial and they replicate at a much faster rate than
the normal human cells (Bignold, 2007). There-
fore, it is reasonable to assume that the rate of telo-
mere loss is higher in the breast cancer cells com-
pared with normal human cells, thereby leading to
more rapid telomere shortening in the breast can-
cer cells.
Earlier studies examined the telomere length in
breast cancer by terminal restriction fragment
analysis in Southern blotting (Odagiri et al., 1994;
Figure 4. Differential mRNA expression of telomere associated proteins by real time RT-PCR. The val-
ues on the y-axis are normalized to the 18 s rRNA expression. A: TRF1 mRNA expression in comparison
between grades of tumor tissues. B: POT1 mRNA expression in comparison between grades of tumor tis-
sues. C: Tankyrase 1 mRNA expression in comparison between grades of tumor tissues. *P < 0.01.
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Rha et al., 1999). But these studies showed incon-
clusive results regarding associations with clinico-
pathological features like grading, hormonal recep-
tor status, etc. It is also reported that telomere
shortening in breast carcinomas are associated with
histological grading (Odagiri et al., 1994) and
increased genomic instability and metastasis (Grif-
fith et al., 1999). Telomere shortening was also cor-
related with poor prognosis in several types of can-
cer (Griffith et al., 1999). O’Hagan et al., (2002)
demonstrated that telomere dysfunction is a major
cause of chromosome instability using aCGH.
They examined chromosomal gains and losses in
mTerc2/2 trp531/2 mice and found that telomere
dysfunction results in segmental gains and losses
that drive epithelial carcinogenesis in the mouse
model (O’Hagan et al., 2002) similar to that ones
seen in human epithelial tumors. This study sup-
ports the hypothesis that telomere-based crisis and
associated breakage-fusion-bridge cycles drive
chromosomal instability in cancer cells (Raptis and
Bapat, 2006).
Breast cancer is assumed to progress as a linear
model with poorly-differentiated (Grade III) breast
tumors would developing from moderately- (Grade
II) and well-differentiated (Grade I) tumors. Ear-
lier studies have shown that allelic imbalances
were greater in the higher grades compared to the
lower grades (Ellsworth et al., 2008). Our data by
aCGH supports this observation. However, the ma-
jority of the observed genetic alterations were not
identical among different grades with only few
common genetic modifications.
Genetically unstable breast cancers have also
been associated more frequently with ER- and PR-
receptor negative breast cancers (Kronenwett
et al., 2006). Breast cancer patients with tumors
that are ER-positive and/or PR-positive have lower
risks of mortality and better prognosis after their
diagnosis compared with women with ER-negative
and/or PR-negative disease (Dunnwald et al.,
2007). In the present study, higher telomere dys-
function was observed in ER-negative tumors
supporting the complex nature of such tumors
(Table 1).
It is known that telomerase is activated by tumor
cells to ensure survival of the cancer cells with
genomic instability (Campisi et al., 2001). Some
studies have shown the association of telomerase
activity with tumor type, nodal metastasis (Roos
et al., 1998; Mokbel et al., 1999), high cellular pro-
liferation (Mokbel et al., 1999), large tumor size,
and lymphovascular invasion in invasive breast
cancer (Bednarek et al., 1997; Roos et al., 1998;
Mokbel et al., 2000). For the first time, as far as we
are aware of, the present study has shown greater
telomerase activity in the higher grades (Grades II
and III) of breast cancers than the lower grade
(Grade I). One earlier study has shown that higher
grades of tumors have more telomerase positive
cells detected in the form of increased hTERT
expression (Kirkpatrick et al., 2003a). Greater telo-
mere shortening in the higher grades could be an
effect of rapid proliferation compared with the
slowly proliferating lower grade tumors. Higher
telomere loss in the higher grades may probably
initiate a feedback mechanism to increase the telo-
merase activity compared with the lower grades.
Accordingly, the cells in the higher grades showed
increased telomerase activity than the lower grades
in our study. Moreover, there may be a selection
pressure for telomerase-positive cells in the higher
grades allowing the telomerase positive cells
bypass the restriction of proliferation common in
cells with critically short telomeres (Clark et al.,
1997). Additionally, we found detectable telomer-
ase activity in the adjacent apparently normal
tissues indicating that they are not completely non-
cancerous. In earlier studies, hTERT expression
was seen in the adjacent tissues (Kirkpatrick et al.,
2003b; Hines et al., 2005). Adjacent tissues could
be in the initial stages of malignant transformation
since telomerase reactivation has been shown as an
early event in breast carcinogenesis (Shpitz et al.,
1999). This proposition is supported by our data
that the telomerase activity in the adjacent tissues
also followed a similar trend as the cancerous tis-
sues. The tissues adjacent to the aggressive Grade
III tumors showed greater telomerase activity than
the less aggressive Grade I tumors. The aggressive
cells in higher grades probably have greater tissue
invasion and infiltration resulting in spill over of
cancerous cells into the adjacent tissues and hence
the detectable telomerase activity. On the other
hand, it may also indicate initiation of tumorigene-
sis in these tissues.
TRF1 is known to protect telomeres and inhibit
telomere replication. Thus, the decreased TRF1
probably facilitates the access of telomerase to
telomeres. There was nonsignificant decrease in
the levels of TRF1 in the malignant tissues in our
study which is in agreement with earlier studies
(Saito et al., 2002; Salhab et al., 2008). Further-
more, the decreased TRF1 mRNA expression in
the higher grades accompanied by telomere short-
ening suggests a possible transcriptional suppres-
sion of TRF1 to release telomerase from negative
regulation. It has been shown that nuclear over-
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expression of Tankyrase 1 leads to poly(ADP-ribosyl)
ation of TRF1 and loss of TRF1 with consequen-
tial increased telomerase access and telomere elon-
gation (Donigian and de Lange, 2007). Consistent
with the reports by Gelmini et al. (2004), we
observed significantly higher levels of Tankyrase 1
in advanced tumors. Furthermore, for the first time
we report a correlation of Tankyrase 1 expression
to the histopathological grades where there is a
grade dependent increase in Tankyrase 1. The
increased expression of Tankyrase 1 and decreased
expression of TRF1 in higher grades act in syner-
gism at the telomeres and have a prominent role in
tumor progression and aggressiveness.
Presence of telomerase activity and grade de-
pendent expression of telomere-related genes
(data not shown) in the tissues adjacent to the ma-
lignant tissues reiterates our proposition that the
apparently normal tissues next to the malignant tis-
sues may not be completely normal. We speculate
that surgical resection margins, which may appear
histologically normal might harbor potentially neo-
plastic cells, possibly through infiltration of tumor
cells into the adjacent tissues beyond the surgical
cut margin (Fig. 5). There are many incidences of
recurrence of cancer after lumpectomy in the adja-
cent tissues previously thought to be histologically
normal. Adjacent mammary epithelium might not
have been completely removed during lumpec-
tomy for invasive carcinoma or ductal carcinoma in
situ and the adjacent cells may subsequently pro-
gress to form another carcinoma. It is therefore
essential to find prognostic indicators for recur-
rence in the morphologically normal epithelium.
Earlier studies have revealed that patients with
loss of heterozygosity in their normal tissues are
more likely to have a tumor recurrence than
patients whose normal tissues are not genetically
aberrant (Deng et al., 1996). In depth analysis of
our aCGH data are underway to determine the
gene loss or gains in breast tumors. Hence, it is
necessary to identify patients who would be at risk
of recurrence in the adjacent tissues, so as to bene-
fit from the more aggressive local therapy or coun-
seling about their higher risk for local failure.
Therefore, in addition to histopathological analy-
sis, other molecular targets such as telomere dys-
function and expression of telomere related genes
should be used as an integrated strategy to classify
the tissues adjacent to tumor tissues as normal.
Although histopathological grading is an impor-
tant factor for the risk assessment in patients with
breast cancer, it could be subjective and a large
proportion of tumors are characterized as interme-
diate-grade tumors, making the best treatment mo-
dality inaccurate. An association was observed
between the telomere dysfunction and the grade
of differentiation of breast cancer in this study.
The data presented in this study show that telo-
mere dysfunction when used as an adjunct to con-
ventional histopathological assessment might pro-
vide clinically relevant information with respect to
Figure 5. A: Haematoxylin and eosin stained paraffin of normal and tumor tissues showing different his-
tological grades. (a) Normal, (b) Grade I, (c) Grade II, (d) Grade III. B: Schematic representation of tumor
(solid black) with surgical cut margins and the normal area (white) with possible infiltration of cancer cells
into the adjacent normal tissues in Grade I, Grade II, and Grade III tumors.
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the degree of malignancy. Therefore, telomere
dysfunction could also be used as a marker for the
aggressiveness of the tumors.
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